What is the date of the report on share capital and voting rights provided by Cellectis?

The report on share capital and voting rights was provided by Cellectis on April 30, 2024.

Monthly information on share capital and company voting rights

In a recent press release, Cellectis provided information on their share capital and company voting rights for April 30, 2024.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

In a recent press release, Cellectis provided information on their share capital and company voting rights for April 30, 2024. The total number of shares in the capital was reported as 71,955,535 with a total number of voting rights at 77,891,229. This data was disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority.

Argus Session date unavailable

-7.46% session move Open Argus

Details

News Market Reaction – CLLS

The recorded move for CLLS in the trading session of this news was -7.46%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/06/2024 - 04:30 PM EDT

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, May 06, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
04/30/2024	71,955,535	77,891,229

For further information on Cellectis, please contact:    

Media contact:      

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com 

Investor Relations contacts:      

Arthur Stril, Chief Financial Officer (interim), +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 

Attachment

Voting_Rights_PR_April_2024_EN_

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the total number of shares in the capital for Cellectis as of April 30, 2024?

The total number of shares in the capital for Cellectis as of April 30, 2024, was reported to be 71,955,535.

How many voting rights does Cellectis have as of April 30, 2024?

Cellectis had a total of 77,891,229 voting rights as of April 30, 2024.

What is the ISIN code for Cellectis?

The ISIN code for Cellectis is FR0010425595.

Who can be contacted for media inquiries regarding Cellectis?

For media inquiries regarding Cellectis, you can contact Pascalyne Wilson, Director of Communications, at +33 (0)7 76 99 14 33 or Patricia Sosa Navarro, Chief of Staff to the CEO, at +33 (0)7 76 77 46 93.

Who are the Investor Relations contacts for Cellectis?

The Investor Relations contacts for Cellectis are Arthur Stril, the Chief Financial Officer (interim), at +1 (347) 809 5980 and Ashley R. Robinson from LifeSci Advisors at +1 617 430 7577.

Keep reading

Trending in the feed

IONQ

IonQ to Acquire Elisity to Accelerate Zero Trust for the Quantum Era Open the live feed